Volume | 2,720,444 |
|
|||||
News | - | ||||||
Day High | 28.40 | Low High |
|||||
Day Low | 27.68 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Royalty Pharma PLC | RPRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
28.25 | 27.68 | 28.40 | 27.82 | 28.16 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
22,791 | 2,720,444 | $ 28.03 | $ 76,256,311 | - | 25.92 - 36.19 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:48:14 | 25 | $ 27.70 | USD |
Royalty Pharma PLC Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
16.62B | 597.43M | - | 2.35B | 1.13B | 1.90 | 14.65 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Royalty Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RPRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 28.37 | 28.595 | 27.425 | 27.87 | 2,160,619 | -0.55 | -1.94% |
1 Month | 30.27 | 30.80 | 27.425 | 28.99 | 2,357,871 | -2.45 | -8.09% |
3 Months | 29.11 | 31.655 | 27.35 | 29.66 | 2,780,513 | -1.29 | -4.43% |
6 Months | 27.47 | 31.655 | 26.07 | 28.76 | 2,552,217 | 0.35 | 1.27% |
1 Year | 36.12 | 36.19 | 25.92 | 29.67 | 2,421,931 | -8.30 | -22.98% |
3 Years | 42.88 | 47.10 | 25.92 | 36.18 | 2,110,697 | -15.06 | -35.12% |
5 Years | 45.90 | 57.50 | 25.92 | 38.31 | 2,135,898 | -18.08 | -39.39% |
Royalty Pharma Description
Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. |